Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
HRD
i
Other names:
Homologous Recombination Deficiency
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related biomarkers:
Others
‹
›
Associations
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
HRD
Ovarian Cancer
HRD
Ovarian Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
Eur J Cancer - 3 weeks (New B)
bevacizumab + olaparib
Sensitive
:
A1
Eur J Cancer - 3wk
bevacizumab + olaparib
Sensitive: A1 - Approval
Eur J Cancer - 3 weeks
bevacizumab + olaparib
Sensitive
:
A1
Eur J Cancer - 3 weeks - (New B)
HRD
Fallopian Tube Cancer
HRD
Fallopian Tube Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
HRD
Peritoneal Cancer
HRD
Peritoneal Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
HRD
Peritoneal Cancer
HRD
Peritoneal Cancer
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
HRD
Fallopian Tube Cancer
HRD
Fallopian Tube Cancer
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
HRD
Ovarian Cancer
HRD
Ovarian Cancer
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
HRD
Prostate Cancer
HRD
Prostate Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
C1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
C1
HRD
Ovarian Cancer
HRD
Ovarian Cancer
rucaparib
Sensitive: A2 - Guideline
rucaparib
Sensitive
:
A2
rucaparib
Sensitive: A2 - Guideline
rucaparib
Sensitive
:
A2
HRD
Ovarian Cancer
HRD
Ovarian Cancer
bevacizumab
Sensitive: A2 - Guideline
bevacizumab
Sensitive
:
A2
bevacizumab
Sensitive: A2 - Guideline
bevacizumab
Sensitive
:
A2
HRD
Ovarian Cancer
HRD
Ovarian Cancer
olaparib
Sensitive: B - Late Trials
olaparib
Sensitive
:
B
olaparib
Sensitive: B - Late Trials
olaparib
Sensitive
:
B
HRD
Ovarian Cancer
HRD
Ovarian Cancer
ABT-888
Sensitive: B - Late Trials
ABT-888
Sensitive
:
B
ABT-888
Sensitive: B - Late Trials
ABT-888
Sensitive
:
B
HRD
Ovarian Cancer
HRD
Ovarian Cancer
atezolizumab
Resistant: B - Late Trials
atezolizumab
Resistant
:
B
atezolizumab
Resistant: B - Late Trials
atezolizumab
Resistant
:
B
HRD
Ovarian Cancer
HRD
Ovarian Cancer
CPB
Sensitive: B - Late Trials
CPB
Sensitive
:
B
CPB
Sensitive: B - Late Trials
CPB
Sensitive
:
B
HRD
Breast Cancer
HRD
Breast Cancer
CX-5461
Sensitive: B - Late Trials
CX-5461
Sensitive
:
B
CX-5461
Sensitive: B - Late Trials
CX-5461
Sensitive
:
B
HRD
Ovarian Cancer
HRD
Ovarian Cancer
CX-5461
Sensitive: B - Late Trials
CX-5461
Sensitive
:
B
CX-5461
Sensitive: B - Late Trials
CX-5461
Sensitive
:
B
HRD
Prostate Cancer
HRD
Prostate Cancer
niraparib
Sensitive: B - Late Trials
niraparib
Sensitive
:
B
niraparib
Sensitive: B - Late Trials
niraparib
Sensitive
:
B
HRD
Triple Negative Breast Cancer
HRD
Triple Negative Breast Cancer
olaparib
Sensitive: C1 - Off-label
olaparib
Sensitive
:
C1
olaparib
Sensitive: C1 - Off-label
olaparib
Sensitive
:
C1
HRD
HER2 Negative Breast Cancer
HRD
HER2 Negative Breast Cancer
olaparib
Resistant: C1 - Off-label
olaparib
Resistant
:
C1
olaparib
Resistant: C1 - Off-label
olaparib
Resistant
:
C1
HRD
Ovarian Cancer
HRD
Ovarian Cancer
tislelizumab + pamiparib
Sensitive: C2 – Inclusion Criteria
tislelizumab + pamiparib
Sensitive
:
C2
tislelizumab + pamiparib
Sensitive: C2 – Inclusion Criteria
tislelizumab + pamiparib
Sensitive
:
C2
HRD
Triple Negative Breast Cancer
HRD
Triple Negative Breast Cancer
tislelizumab
Sensitive: C2 – Inclusion Criteria
tislelizumab
Sensitive
:
C2
tislelizumab
Sensitive: C2 – Inclusion Criteria
tislelizumab
Sensitive
:
C2
HRD
Ovarian Cancer
HRD
Ovarian Cancer
bevacizumab + niraparib
Sensitive: C2 – Inclusion Criteria
bevacizumab + niraparib
Sensitive
:
C2
bevacizumab + niraparib
Sensitive: C2 – Inclusion Criteria
bevacizumab + niraparib
Sensitive
:
C2
HRD
Non Small Cell Lung Cancer
HRD
Non Small Cell Lung Cancer
talazoparib
Resistant: C3 – Early Trials
talazoparib
Resistant
:
C3
talazoparib
Resistant: C3 – Early Trials
talazoparib
Resistant
:
C3
HRD
Gastric Cancer
HRD
Gastric Cancer
nivolumab
Sensitive: C3 – Early Trials
nivolumab
Sensitive
:
C3
nivolumab
Sensitive: C3 – Early Trials
nivolumab
Sensitive
:
C3
HRD
Triple Negative Breast Cancer
HRD
Triple Negative Breast Cancer
pembrolizumab + niraparib
Sensitive: C3 – Early Trials
pembrolizumab + niraparib
Sensitive
:
C3
pembrolizumab + niraparib
Sensitive: C3 – Early Trials
pembrolizumab + niraparib
Sensitive
:
C3
HRD
Prostate Cancer
HRD
Prostate Cancer
nivolumab + ipilimumab
Sensitive: C3 – Early Trials
nivolumab + ipilimumab
Sensitive
:
C3
nivolumab + ipilimumab
Sensitive: C3 – Early Trials
nivolumab + ipilimumab
Sensitive
:
C3
HRD
Prostate Cancer
HRD
Prostate Cancer
abiraterone acetate
Resistant: C3 – Early Trials
abiraterone acetate
Resistant
:
C3
abiraterone acetate
Resistant: C3 – Early Trials
abiraterone acetate
Resistant
:
C3
HRD
Ovarian Cancer
HRD
Ovarian Cancer
ABT-767
Sensitive: C3 – Early Trials
ABT-767
Sensitive
:
C3
ABT-767
Sensitive: C3 – Early Trials
ABT-767
Sensitive
:
C3
HRD
Ovarian Cancer
HRD
Ovarian Cancer
PARP inhibitor
Sensitive: C3 – Early Trials
PARP inhibitor
Sensitive
:
C3
PARP inhibitor
Sensitive: C3 – Early Trials
PARP inhibitor
Sensitive
:
C3
HRD
Prostate Cancer
HRD
Prostate Cancer
talazoparib
Sensitive: C3 – Early Trials
talazoparib
Sensitive
:
C3
talazoparib
Sensitive: C3 – Early Trials
talazoparib
Sensitive
:
C3
HRD
Triple Negative Breast Cancer
HRD
Triple Negative Breast Cancer
carboplatin + paclitaxel + non-pegylated liposomal doxorubicin
Sensitive: C3 – Early Trials
carboplatin + paclitaxel + non-pegylated liposomal doxorubicin
Sensitive
:
C3
carboplatin + paclitaxel + non-pegylated liposomal doxorubicin
Sensitive: C3 – Early Trials
carboplatin + paclitaxel + non-pegylated liposomal doxorubicin
Sensitive
:
C3
HRD
Pancreatic Cancer
HRD
Pancreatic Cancer
anlotinib + sintilimab
Sensitive: C3 – Early Trials
anlotinib + sintilimab
Sensitive
:
C3
anlotinib + sintilimab
Sensitive: C3 – Early Trials
anlotinib + sintilimab
Sensitive
:
C3
HRD
Squamous Cell Carcinoma of Head and Neck
HRD
Squamous Cell Carcinoma of Head and Neck
PD1 inhibitor
Sensitive: C3 – Early Trials
PD1 inhibitor
Sensitive
:
C3
PD1 inhibitor
Sensitive: C3 – Early Trials
PD1 inhibitor
Sensitive
:
C3
HRD
Triple Negative Breast Cancer
HRD
Triple Negative Breast Cancer
D19466
Sensitive: C3 – Early Trials
D19466
Sensitive
:
C3
D19466
Sensitive: C3 – Early Trials
D19466
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login